Format

Send to

Choose Destination
Expert Opin Pharmacother. 2008 Apr;9(6):887-900. doi: 10.1517/14656566.9.6.887.

Neuroprotectants in stroke therapy.

Author information

1
Department of Biochemistry, National University of Singapore, Yong Loo Lin School of Medicine, Singapore. bchjeya@nus.edu.sg

Abstract

BACKGROUND:

Over the past 10 years clinical trials aimed at finding suitable neuroprotectants against the debilitating effects of stroke have met with no success. Identifying novel neuroprotectants that can reverse the effects of stroke is becoming a challenge to both clinicians and scientists.

OBJECTIVES:

This review focused on the current status on the topic and highlights some of the neuroprotectants that are worth examining or re-examining further.

METHODS:

Recent findings on the subject have been included.

CONCLUSION:

Many neuroprotectants that have worked in preclinical evaluations have been found to be ineffective in clinical trials. Nevertheless, some of them are still considered to be worth re-examining. Non-coding small RNAs (riboregulators) as novel therapeutic leads have also been introduced in this review.

PMID:
18377333
DOI:
10.1517/14656566.9.6.887
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center